Stratatech Initiates Second Clinical Trial of StrataGraft(R) Skin Substitute  
9/23/2011 10:31:17 AM

MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a leader in regenerative medicine, today announced that it has initiated its second multicenter clinical trial of the company’s StrataGraft® skin substitute. The clinical trial will assess the safety and clinical utility of the StrataGraft® skin substitute in the long-term treatment of patients with severe second-degree burns.